The cure of leprosy versus recurrence magnitude;A cura da hanseniase x magnitude das recidivas

Anais Brasileiros de Dermatologia

Volumn 72, Issue 1, 1997, Pages 63-69

  De Oliveira, Maria Leide W ^a,b  

^a Doutora em Dermatologia   (Brazil)

^b NONE   (Brazil)

Author keywords

leprosy; recurrence

Indexed keywords

LEPROSTATIC AGENT; LEPROSY VACCINE;

ARTICLE; DRUG RESISTANCE; HUMAN; LEPROSY; RECURRENCE RISK;

EID: 0030932511     PISSN: 03650596     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Stedman Medical Dictionary.Baltimore: The Williams & Company (trad) Guanabara Koogan, 1979.
2. Blackiston B. Dicionário Médico. 2a ed. São Paulo: André Ed., 1982.
3. Ramos e Silva J. A chimiotherapia da lepra; seu estado actual. An bras Dermatol 1926;2(2):17-28.
4. Mouat FJ. Notes on native remedies. No. 1. The chaulmoogra. Indian Annals of Medical Sciences 1854;(1):646-52.
5. Hollman HT. The fatty acids of chaulmoogra oil in the treatment of leprosy and other diseases. Arch Dermatol Syphil 1992;(5):94.
6. Jacobson RR. Treatment of leprosy. In: Hastings CR. Leprosy. Edinburgh London Melbourne and N.York: Churchill Livingstone, 1985:113-22.
7. Levy L. The activity of chaulmoogra acids agains M. leprae. Am Rev Respir Dis 1975;(111):703-5.
8. Connal A. Some notes on the treatment of leprosy. J Trop Med Hyg 1918;(22):37-40.
9. Wade HW, Lara CB. Studies on negative leprosy III: the problem of relapses. J Phil Is Med Assoc 1927;(29):19-30.
10. Bechelli LM, Rotberg A. Chaulmoogra in leprosy: a study of 2.201 patients. Arq Serv Nac Lepr 1946;4:353-74.
11. Faget GH, Johansen FA, Ross H. Sulfanilamide in the treatment of leprosy. Public Health Rep 1942;57:1892-9.
12. Faget GH, Pogge RC, Johansen Fa et al. The promin treatment of leprosy: a progress report. Public Health Rep 1943;58:1729-41.
13. De Souza Lima L. Resultados atuais da sulfonoterapia no Sanatório Padre Bento. Rev Bras Leprol 1948;16(2):75-85.
14. Rabelo FE. Simpósio sobre a experiência brasileira com a sulfonoterapia. Arq Min Leprol 1942;12:285-426.
15. Erickson PT. Relapse following apparent arrest of leprosy by sulfone therapy. Int J Lepr Other Mycobact Dis 1951;19:63-74.
16. Lowe J. The late results of sulphone treatment of leprosy in E. Nigeria Lepr Rev 1954;25:113.
17. Rodriguez JN. Relapses after sulphone therapy in leprosy of the lepromatous type. Int J Lepr Other Mycobact Dis 1958;26: 305-12.
18. Quagliato R, Bechelli LM, Marques RM. Bacterial negativity and reactivation (relapse) of lepromatous outpatients under sulfone treatment. Int J Lepr Other Mycobact Dis 1970;38(3):250-63.
19. Quagliato R, Berquó E, Leser W. Lepromatosos em tratamento sulfônico. Rev Bras Leprol 1961;29(1):19-30.
20. WHO. Expert Committee on Leprosy. Third Report. WHO Tech Rep Series, 1966;13.
21. Brasil. MS/DNDS. Tratamento e profilaxia da hanseníase. NT-SSRGS-7. 1976 (Mimeo).
22. Brasil. MS/DNDS. Legislação em saúde. Portaria Ministerial 165, de 14 de maio de 1976.
23. Shepard CC. The experimental disease that follows the injection of human leprosy into footpads of mice. J Exp Med 1960; 112:445-54.
24. Waters MFR, Rees RJW McDougall AC, Weddell AGM. Ten years of dapsone in leprosy: a clinical, bacteriological and hislological assessment and the finding of viable leprosy bacilli. Lepr Rev 1974;45:288-98.
25. Pearson JM, Rees RJ, Waters MF. Sulphone resistance in leprosy. A review of one hundred proven clinical cases. The Lancet 1975;2:69-72.
26. Talhari S, Damasco MHS, Souza-Cunha MG, Schettini APM, Andrade LMC. Sulfonoresistência: comprovação laboratorial em 6 casos. An bras Dermatol 1985;60(4):175-8.
27. Talhari S, Damasco MHS, Schettini APM et al. Secondary dapsone resistant leprosy in Brazil: a preliminary report. Lepr Rev 1986;57-8.
28. WHO. Expert Committee on leprosy. Fourth report. Technical report series, 1970;459.
29. Aguiar Pupo J. Conccituação da moderna quimioterapia da hanseníase. Bol Div Nac Derm Sanit 1968;(3/4):82-97.
30. Languillon J, Ramanujan K, Barba-Rubio J et al. Comité de terapia. Recomendações do X Congresso Internacional de Lepra Bergen Bol Ser Div Lepr 1973;(2-3-4):42-7.
31. De Souza Lima, Opromolla D. First results on the treatment of leprosy with rifamycin SV. Chemotherapy 1963;668-78.
32. Shepard CC, Levy L, Fasal P. Rapid bactericidal activity of rifampin on M. leprae. Am J Trop Med Hyg 1972;21:446-9.
33. Mattos O. Clínica e terapêutica da lepra. Bol Div Nac Lepr 1974; (1-4):71-89.
34. Belda W, Margarido LC, Marlet JM et al. Estudo comparativo das medias móveis dos IB e IM em pacientes HV, tratados pela rifampicina e DDS. Rev Saúde Pública 1979;13: 80-91.
35. Brasil-MS/DNDS. Guia para controle da hanseníase. Série A: normas e manuais técnicos, 1983;6.
36. Freekerson E, Rosenfeld M, Leprosy erradication project of Malta.Chemotherapy 1977;23:356-86.
37. Jopling WH, Riddley MJ, Boninni E, de Pasquale G. A follow-up investigation of the Malta Project. Lepr Rev 1984, 55:247-53.
38. Waters MFR. Relapse following various types of multidrug therapy in multibacillary leprosy. Lepr Rev 1995;66(1):1-9.
39. Bahong J, Perani EG, Petinon C, Grosset JH. Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs. Int J Lepr Other Mycobact Dis 1992; 60(4):556-61.
40. WHO/THELEP. Persisting M. leprae among THELEP trials patients in Bamako and Chingleput. Lepr Rev 1987;58:325-37.
41. Rees RJW, Waters MFR, Pearson JMH, Helmy HS, Laring ABG. Long-term treatment of dapsone resistant leprosy with rifampin. clinical and bacteriological studies. Int J Lepr Other Mycobact Dis 1976;44:159-69
42. Pattyn SR, Andre PS, Ferraci C, Baquillon G. Comparative study of two regimens-combined chemotherapy of one year duration in MB leprosy: results after 4 and 5 years follow-up. Int J Lepr Other Mycobact Dis 1974;52(3):297-303.
43. WHO. Chemotherapy of leprosy for control programmes. WHO technical report series, 1982;675.
44. WHO. Study Group (epidemiology of leprosy in relation to control. WHO technical report series, 1985;716.
45. WHO. A guide to leprosy control. 2nd ed. Geneve, 1988.
46. WHO. Leprosy unit. Chemotherapy of leprosy. WHO technical report series, 1994;847.
47. Brasil. DNDS/MS. Proposta de implantação dos esquema de poliquimioterapia (OMS), 1986 (MIMEO).
48. Oliveira MLW, Oliveira GP, Andrade VLG et al. Gradual setting up multidrug therapy in Brazil. Int J Lepr Other Mycobact Dis 1989;(57)(Suppl):333.
49. Brasil. MS/FNS. Legislação sobre o controle de doenças na área de Dermatologia Sanitária. 4a ed. CENEPI, 1993.
50. Brasil-MS/FNS/CNDS. Guia de controle da hanseníase. COMED/ASPLAN/FNS. 2 ed. 1994: 156p.
51. Waters MFR. The rate of relapse in lepromatous leprosy following completion of twenty years of supervised sulphone therapy. Lepr Rev 1986;57:101-7.
52. Kurtz XM, Declerq EE, Vellut CM. Rate and time distribution of relapses in multibacillary leprosy. Int J Lepr Other Mycobact Dis 1989;57(3):599-606.
53. Cartel JL, Boutin JP, Spiegel A, Plichart R, Roux JF. Longitudinal study of relapse of leprosy in polynesian multibacillary patients. Lepr Rev 1991;62(2):186-92.
54. Becx-Bleumink M. Relapses in leprosy patients after release from dapsone monotherapy: experience in Ethiopia. Int J Lepr Other Mycobact Dis 1992;60:1611-72.
55. WHO. The leprosy unit division of control of tropical diseases. Risk of relapse in leprosy. WHO/CTD/LEP/94.1, 1994.
56. Becx-Bleumink M. Relapses among leprosy patients treated with MDT: experience in the ALERT Center Ethiopia. Practical difficulties with diagnosing relapses. Int J Lepr Other Mycobact Dis 1992;60(3):421-35.
57. Marchoux Chemotherapy Study Group. Relapse rates in multibacillary leprosy patients after stopping treatment with Rifampin- containing combined regimens. Int J Lepr Other Mycobact Dis 1992;60(4):525-35.
58. Janiet P, Baohong J, Marchoux Chemotherapy Study Group. Relapse after long-term follow-up of multibacillary patients treated by WHO multidrug regimen. Int J Lepr Other Mycobact Dis 1995;63(2):195-201.
59. Gangahharam PRJ. Drug resistance in mycobacteria. CRC/ USA. Press. Inc, 1994.
60. Dias LC. Sulfono-resistência primária e secundária. Estudo clínico. Manaus 1989; monografia (Mimeo).
61. Grosset J, Guelpa-Lauras CC, Bobin P, Brucker G et al. Study of 39 documented relapses of multibacillary leprosy treatment with rifampin. Int J Lepr Other Mycobact Dis 1989; 57:507-614.
62. Guelpa-Lauras CC, Grosset J, Constant-Desportes M, Brucker G. Nine cases of rifampin-resistant leprosy. Int J Lepr Other Mycobact Dis 1984;52:101-2.
63. Grosset JH, Guelpa-Lauras CC. Activity of rifampin in infections of normal mice with M. leprae. Int J Lepr Other Mycobact Dis 1987,55(4)(Suppl):847-51.
64. Opromolla D, Costa HC, Oliveira PRD. Resistência medicamentosa múltipla secundária na hanseníase Hansen Int 1993;18(2):11-6.
65. Almeida JG, Jesudasan K, Christian M, Chacko GG. Relapse rates in lepromatous leprosy according to treatment regularity. Int J Lepr Other Mycobact Dis 1985;54(1):16-20.
66. Shepard CC, Rees RJ, Levy L et al. Susceptibility of strains of M. leprae isolated prior to 1977 from patients with previously untreated lepromatous leprosy. Int J Lepr Other Mycobact Dis 1986;54:11-5.
67. Bahong J. Drug resistance in leprosy: a review. Lepr Rev 1985;56:265-78.
68. Bigger JW. The treatment of staphyloccocal infections with penicillin by intermittent sterilization. The Lancet 1944;2:497-500.
69. Mc Dermott W. Microbial persistence. Yale J Biol Med 1958; 30:279-91.
70. Toman K. Bacterial persistence in leprosy. Int J Lepr Other Mycobact Dis 1981;49(2):205-17.
71. Mitchson DA, Dickinson JM. Bactericidal mechanism in short-course chemotherapy. Bull Int Union Tuberc 1979;53: 254-9.
72. Muir E. Leprosy. A self-healing disease. The Lancet 1924; (Febr):277-80.
73. Revankar CR, Ganapati CR. Interpretation of beneficiaries VS relapse in multidrug therapy programme. Lepr Rev 1995;66(4): 325-6.
74. Noordeen SK. Relapse in lepromatous leprosy. Lepr Rev 1971; 42:43-8.
75. Brasil/MS/FNS/PNCT. Relatório de avaliação operacional e epidemiológica do PNCT na década de 80. 1992 (Mimeo).
76. Penna MLF. Tuberculose, assistência ou controle? Tese de Mestrado. Instituto Medicina Social/UERJ, 1988, 130p.